5,7-Dihydroxy-8-[2-hydroxy-5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-Yl)phenyl]-2-(4-hydroxyphenyl)-4-benzopyrone

CAS : 21763-71-3

Ref. 3D-FD161087

Informations sur le produit

• Nom: 5,7-Dihydroxy-8-[2-hydroxy-5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-Yl)phenyl]-2-(4-hydroxyphenyl)-4-benzopyrone
• Synonymes: Sequoiaflavone, 3''',8-Biflavone, 4',4''',5,5'',7-pentahydroxy-7''-methoxy- (8CI), 3′′′,8-Biflavone, 4′,4′′′,5,5′′,7-pentahydroxy-7′′-methoxy-, 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-(2-hydroxy-5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)phenyl)-2-(4-hydroxyphenyl)-, 5,7-Dihydroxy-8-[2-hydroxy-5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)phenyl]-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, 5,7-dihydroxy-8-[2-hydroxy-5-(5-hydroxy-7-methoxy-4-oxo-4H-chromen-2-yl)phenyl]-2-(4-hydroxyphenyl)-4H-chromen-4-one, 7-O-Methylamentoflavone, Brakerin, Brn 1445484, IdB-1028, Lf-2646, Sequojaflavone

Description

Combination drug therapy is the simultaneous use of two or more drugs in order to achieve a synergistic effect. This strategy is used when a single drug cannot sufficiently treat an illness and it is desirable to combine them to produce a greater therapeutic effect than would be achieved by any one of the drugs alone. 5,7-dihydroxy-8-[2-hydroxy-5-(5-hydoxy-7-methoxy-4-oxo-4H-1-benzopyran-2yl)phenyl]-2-(4 hydroxyphenyl)-4H benzopyrone (AHB) has been shown to inhibit phosphodiesterase activity in geriatric patients. Magnetic resonance spectroscopy has shown that AHB inhibits geriatric patients' acetate production, which may be due to its inhibition of efflux pump activity. AHB has also been shown to increase camp levels in these patients, which may be due to its inhibition of the

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 552.48 g/mol
• Formule: C₃₁H₂₀O₁₀
• Degré de pureté: Min. 95%